Sanofi to Acquire Fulcrum Therapeutics for $805M
Ticker: FULC · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1680581
| Field | Detail |
|---|---|
| Company | Fulcrum Therapeutics, INC. (FULC) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $240 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, biotech, merger, rare-disease
Related Tickers: SNY
TL;DR
Sanofi buying Fulcrum for $805M cash to boost rare disease pipeline.
AI Summary
Fulcrum Therapeutics, Inc. announced on January 13, 2025, that it has entered into a definitive agreement to be acquired by Sanofi for $8.00 per share in cash, representing a total equity value of approximately $805 million. This acquisition aims to accelerate Sanofi's development of novel therapies for genetically defined diseases.
Why It Matters
This acquisition by a major pharmaceutical company like Sanofi could significantly impact Fulcrum's pipeline and the development of its therapies for rare genetic diseases, potentially bringing new treatments to patients faster.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which introduces a level of uncertainty until completion.
Key Numbers
- $805 million — Acquisition Value (Total equity value of the deal between Sanofi and Fulcrum Therapeutics.)
- $8.00 — Per Share Price (Cash price offered per share of Fulcrum Therapeutics common stock.)
Key Players & Entities
- Fulcrum Therapeutics, Inc. (company) — Company being acquired
- Sanofi (company) — Acquiring company
- $8.00 (dollar_amount) — Per share acquisition price
- $805 million (dollar_amount) — Total equity value of the acquisition
- January 13, 2025 (date) — Date of the announcement and agreement
FAQ
What is the primary reason for Sanofi's acquisition of Fulcrum Therapeutics?
Sanofi is acquiring Fulcrum Therapeutics to accelerate its development of novel therapies for genetically defined diseases, particularly rare diseases.
What is the total value of the acquisition agreement?
The definitive agreement values Fulcrum Therapeutics at approximately $805 million in total equity value.
What is the price per share being offered to Fulcrum Therapeutics shareholders?
Sanofi is offering $8.00 per share in cash for each outstanding share of Fulcrum Therapeutics common stock.
When was the definitive agreement announced?
The definitive agreement was announced on January 13, 2025.
Are there any conditions to closing the acquisition?
Yes, the acquisition is subject to customary closing conditions, including the receipt of regulatory approvals.
Filing Stats: 734 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-01-13 07:00:24
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share FULC Nasdaq Global Market
- $240 million — cts to report that it had approximately $240 million of cash, cash equivalents and marketabl
Filing Documents
- d714885d8k.htm (8-K) — 28KB
- d714885dex991.htm (EX-99.1) — 25KB
- g714885ex99_1p10g1.jpg (GRAPHIC) — 324KB
- g714885ex99_1p11g1.jpg (GRAPHIC) — 257KB
- g714885ex99_1p12g1.jpg (GRAPHIC) — 214KB
- g714885ex99_1p13g1.jpg (GRAPHIC) — 365KB
- g714885ex99_1p14g1.jpg (GRAPHIC) — 314KB
- g714885ex99_1p15g1.jpg (GRAPHIC) — 271KB
- g714885ex99_1p16g1.jpg (GRAPHIC) — 201KB
- g714885ex99_1p17g1.jpg (GRAPHIC) — 284KB
- g714885ex99_1p18g1.jpg (GRAPHIC) — 316KB
- g714885ex99_1p19g1.jpg (GRAPHIC) — 247KB
- g714885ex99_1p1g1.jpg (GRAPHIC) — 397KB
- g714885ex99_1p20g1.jpg (GRAPHIC) — 220KB
- g714885ex99_1p21g1.jpg (GRAPHIC) — 149KB
- g714885ex99_1p2g1.jpg (GRAPHIC) — 548KB
- g714885ex99_1p3g1.jpg (GRAPHIC) — 252KB
- g714885ex99_1p4g1.jpg (GRAPHIC) — 162KB
- g714885ex99_1p5g1.jpg (GRAPHIC) — 292KB
- g714885ex99_1p6g1.jpg (GRAPHIC) — 253KB
- g714885ex99_1p7g1.jpg (GRAPHIC) — 219KB
- g714885ex99_1p8g1.jpg (GRAPHIC) — 178KB
- g714885ex99_1p9g1.jpg (GRAPHIC) — 237KB
- 0001193125-25-004942.txt ( ) — 8033KB
- fulc-20250113.xsd (EX-101.SCH) — 3KB
- fulc-20250113_lab.xml (EX-101.LAB) — 17KB
- fulc-20250113_pre.xml (EX-101.PRE) — 11KB
- d714885d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits The following exhibit is furnished herewith: Exhibit No. Description 99.1 Corporate Presentation dated January 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FULCRUM THERAPEUTICS, INC. Date:January 13, 2025 By: /s/ Alex C. Sapir Name: Alex C. Sapir Title: President and Chief Executive Officer